Enzymatic glycan remodeling–metal free click (GlycoConnect™) provides homogenous antibody-drug conjugates with improved stability and therapeutic index without sequence engineering

Antibody-drug conjugates (ADCs) are increasingly powerful medicines for targeted cancer therapy. Inspired by the trend to further improve their therapeutic index by generation of homogenous ADCs, we report here how the clinical-stage GlycoConnect™ technology uses the globally conserved N-glycosylati...

Descripción completa

Detalles Bibliográficos
Autores principales: Wijdeven, Marloes A., van Geel, Remon, Hoogenboom, Jorin H., Verkade, Jorge M. M., Janssen, Brian M. G., Hurkmans, Inge, de Bever, Laureen, van Berkel, Sander S., van Delft, Floris L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Short Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9154768/
https://www.ncbi.nlm.nih.gov/pubmed/35634725
http://dx.doi.org/10.1080/19420862.2022.2078466

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9154768/
https://www.ncbi.nlm.nih.gov/pubmed/35634725
http://dx.doi.org/10.1080/19420862.2022.2078466

Ejemplares similares